Matthew Hager, MD
Endocrinology, Diabetes & Metabolism · Greenville, NCNPI 1841606308
Payments from drug & device makers
Across 447 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Lilly USA, LLC$960
- Novo Nordisk$723
- Abbott$659
- AstraZeneca$577
- Insulet Corporation$435
- plus $4K from 42 others
What the payments were for
- Food & beverage$8,16998%
- Education$1272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,296 in reported general payments places this provider in the 70th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 997 | $1,219,360 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 265 | $235,861 |
| MounjaroTirzepatide | 168 | $208,607 |
| Xigduo XrDapaglifloz Propaned/Metformin | 233 | $172,150 |
| Tresiba Flextouch U-100Insulin Degludec | 223 | $156,575 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 182 | $144,863 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 119 | $135,092 |
| JardianceEmpagliflozin | 141 | $121,945 |
| Tresiba Flextouch U-200Insulin Degludec | 87 | $112,881 |
| TrulicityDulaglutide | 90 | $107,118 |
| JanuviaSitagliptin Phosphate | 118 | $100,110 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 223 | $85,523 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 178 | $83,302 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 47 | $77,955 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $75,954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $723 | $1,295,9161,096 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $960 | $330,408317 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Glyxambi | $101 | $289,406357 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $368 | $235,861265 claims |
| MerckJanuvia, Janumet Xr, Janumet | $86 | $130,713171 claims |
| AstraZenecaFarxiga | $577 | $71,86988 claims |
| AmgenProlia | $1,083 | $24,46414 claims |
| AbbVieSynthroid | $91 | $14,182187 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Greenville
- Mark WarrenGreenville$5M
- Kathryn LucasMorehead City$37.9M
- Mary LawrenceMorehead City$4.9M
- John ParkerWilmington$4.1M
- John BuseChapel Hill$3.8M
- Wendy LaneAsheville$1.9M
- Anthony BarberHickory$1.4M
- Klara KleinChapel Hill$1.3M
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.